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CD4+CD25highFoxp3+ regulatoryT cells (Tregs) can suppress other immune cells and, thus,
are critical mediators of peripheral self-tolerance. On the one hand, Tregs avert autoim-
mune disease and allergies. On the other hand, Tregs can prevent immune reactions
against tumors and pathogens. Despite the importance of Tregs, the molecular mecha-
nisms of suppression remain incompletely understood and controversial. Proliferation and
cytokine production of CD4+CD25− conventionalT cells (Tcons) can be inhibited directly by
Tregs. In addition,Tregs can indirectly suppressTcon activation via inhibition of the stimula-
tory capacity of antigen presenting cells. Direct suppression of Tcons byTregs can involve
immunosuppressive soluble factors or cell contact. Different mechanisms of suppression
have been described, so far with no consensus on one universal mechanism. Controver-
sies might be explained by the fact that different mechanisms may operate depending on
the site of the immune reaction, on the type and activation state of the suppressed target
cell as well as on the Treg activation status. Further, inhibition of T cell effector function
can occur independently of suppression of proliferation. In this review, we summarize the
described molecular mechanisms of suppression with a particular focus on suppression
of Tcons and rapid suppression of T cell receptor-induced calcium (Ca2+), NFAT, and NF-κB
signaling in Tcons byTregs.
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INTRODUCTION: DISCOVERY AND PROPERTIES OF
REGULATORY T CELLS
RegulatoryT cells (Tregs) play an indispensable role in the immune
system as they are involved in the prevention of autoimmune
diseases, allergies, infection-induced organ pathology, transplant
rejection as well as graft versus host disease (GvHD) by sup-
pression of effector T cells and other immune cells (Sakaguchi,
2004). However, Tregs can also dampen immune responses against
tumors, as described for various types of cancer (Zou, 2006;
Curiel, 2008). Conversely, in certain situations, Tregs can also pro-
tect against cancer by controlling cancer-associated inﬂammation
(Gounaris et al., 2009). Therefore, Tregs are subject to intense
investigations.
The history of Tregs begins in 1970 (Gershon and Kondo,
1970). Unfortunately, due to lack of a molecular marker, research
on suppressor T cells was stopped, until many years later Sak-
aguchi et al. (1995) identiﬁed CD25 as a phenotypic marker
for suppressive CD4+ T cells in mice. These suppressive T cells
were named Tregs and were later also found in humans within
the CD4+CD25high T cell population (Baecher-Allan et al., 2001;
Dieckmann et al., 2001; Jonuleit et al., 2001; Levings et al., 2001;
Stephens et al., 2001; Taams et al., 2001). Constitutive expression
of CD25 is restricted to Tregs in naïve mice while in humans,
only cells that highly express CD25 designate Tregs, and acti-
vated T cells acquire intermediate levels of CD25 (Sakaguchi et al.,
1995; Baecher-Allan et al., 2001). Importantly, Foxp3 was iden-
tiﬁed as a lineage-deﬁning transcription factor for Tregs in mice
(Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003) and
humans (Yagi et al., 2004; Roncador et al., 2005). In mice, up
to 90% of Tregs express Foxp3, while resting as well as activated
conventional T cells do not show detectable levels of Foxp3. Anal-
ogous to mice, the majority of human CD4+CD25high Tregs also
express Foxp3. However, in contrast to mice, human conventional
T cells (Tcons) transiently express intermediate levels of Foxp3
upon activation (Pillai et al., 2007), questioning Foxp3 as a spe-
ciﬁc marker for human Tregs. While the necessity of Foxp3 for
suppressive function of Tregs is undisputed, contradictory reports
leave it unclear whether (temporary) Foxp3 expression is sufﬁcient
to confer suppressive abilities to human activated T cells. Some
studies demonstrated suppressive capacities of Foxp3+ activated
human T cells (Walker et al., 2003; Pillai et al., 2007) while others
did not (Gavin et al., 2006; Wang et al., 2007; Allan et al., 2007).
However, activation-induced transient Foxp3 induction in human
Tcons was not observed in other studies (Yagi et al., 2004). These
discrepancies might be due to differences in culture conditions,
such as strength of T cell receptor (TCR) stimulation and pres-
ence of IL-2 or TGF-β. For example, Shevach’s group found that
TCR-induced Foxp3 expression in human naïve Tcons is indeed
dependent on TGF-β, but does not result in a suppressive phe-
notype (Tran et al., 2007). In addition, his group claimed that a
certain antibody clone used for staining of human Foxp3 results
in unspeciﬁc staining of activated T cells, although this is contro-
versial (Pillai and Karandikar, 2008). Conﬂicting results may also
be ascribed to differences in kinetics and level of Foxp3 expression
and, consequently, expression of Foxp3 target genes (Allan et al.,
2008; Zheng et al., 2008).
Foxp3+ Tregs are not a uniformpopulationbut rather comprise
several subphenotypes. The majority of human Tregs displays
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a CCR7−CD45RA− effector/memory phenotype (Beyer and
Schultze, 2007). However, only the naïve CD45RA+ Treg subset
maintains Treg phenotype and function upon ex vivo expan-
sion (Hoffmann et al., 2006). A detailed characterization of the
human Foxp3+ Treg repertoire suggested a further grouping into
CD45RA+Foxp3low resting Tregs, CD45RA−Foxp3high activated
Tregs, and CD45RA− Foxp3low cytokine-secreting Tregs, the lat-
ter being non-suppressive (Miyara et al., 2009). Further, several
subphenotypes of murine Tregs with distinct transcriptional sig-
natureswere found indifferent anatomical locations (Feuerer et al.,
2009, 2010). Diverse Treg subpopulations may apply different sup-
pression mechanisms and speciﬁcally control certain effector cell
types. In this review, we mainly focus on naturally occurring Tregs
(nTregs),which are thymus-derived.Yet peripheral tolerance is not
only ensured by nTregs but also involves various inducedTreg pop-
ulations (iTregs), which seem to play a role mainly in the intestine
(Curotto de Lafaille and Lafaille, 2009).
MOLECULAR MECHANISMS OF Treg-MEDIATED
SUPPRESSION
Tregs can suppress a variety of immune cells including B cells,
NK cells, NKT cells, CD4+, and CD8+ T cells, as well as mono-
cytes and dendritic cells (DCs). In the following, we will focus on
suppression of CD4+CD25− conventional T cells (Tcons).
Upon cell–cell contact, Tregs inhibit TCR-induced prolifera-
tion and IL-2 transcription of Tcons, as shown for murine Tregs
already in 1998 (Thornton and Shevach, 1998). Suppression of
murine (Ermann et al., 2001) or human (Dieckmann et al., 2001)
Tcon proliferation by Tregs can occur directly, i.e., in the absence
of antigen presenting cells (APCs). This direct suppression can
involve immunosuppressive cytokines or other factors; however,
contact-dependent direct suppression has also been described. In
addition,Tregs can inhibit Tcons indirectly by inﬂuencing the acti-
vation status of APCs and therefore activation of Tcons. Based on
these properties, a standard assay to assess Treg function is inhi-
bition of responder Tcon proliferation upon stimulation via the
TCR in the presence of APCs. A main function of Tregs is sup-
pression of activation and expansion of naïve Tcons, but they can
also inhibit activated effector T cells and memory CD4+ (Lev-
ings et al., 2001) and CD8+ (Suvas et al., 2003) T cells. To be
suppressive, Tregs themselves have to be TCR-activated in the
presence of IL-2 (Takahashi et al., 1998; Thornton and Shevach,
1998; de la Rosa et al., 2004; Thornton et al., 2004a,b) while
costimulation via CD28 is dispensable (Takahashi et al., 2000).
However, a more recent study questioned the requirement for
Treg activation: Szymczak-Workman et al. (2009) showed that
TCR-transgenic Tregs were able to suppress Tcons with differ-
ent antigen speciﬁcity in the absence of the Treg-cognate antigen.
Differences in the type of APCs used in the assays, the trans-
genic system, or“pre-activation”by the cell puriﬁcation procedure
might provide an explanation for the controversy. Yet, the study
is in line with other reports that show that Tregs, once active,
can suppress Tcons independently of antigen, leading to so-called
bystander suppression (Thornton and Shevach, 2000; Karim et al.,
2005).
Different mechanisms of Treg-mediated suppression have been
described,mostly on the basis of in vitro suppression assays. These
mechanisms may also operate in vivo depending on the target cell
type and activation status as well as the location and cytokine
and microorganism milieu of the immune reaction. Thus, the
contribution of suppressive mechanisms might be interpreted dif-
ferently depending on the cell types and their activation state
used in in vitro suppression assays. In addition, differences may
occur depending on the readout, as suppressing the production
of certain effector cytokines or the release of cytotoxic granules
in vivo and in vitro can occur without concomitant suppression
of proliferation (Mempel et al., 2006; Schmidt et al., 2011; Sojka
and Fowell, 2011). For example, using another in vivo model, it
was shown that Tcon expansion in response to antigen was sup-
pressed by Tregs relatively late, yet the remaining Tcons still cycled
and produced effector cytokines at these late time points (Klein
et al., 2003). It was suggested that activation and/or expansion
of antigen-speciﬁc Tregs may be a prerequisite for suppression of
Tcons in vivo, as itmight result in sufﬁcient Treg numbers to enable
contactwith target Tcons at the site of the immune response (Klein
et al., 2003).
The describedmechanisms of Treg-mediatedT cell suppression
are summarized in Figure 1 and will be described in more detail
in the following sections.
MODULATION OF APC FUNCTION BY Tregs THROUGH CTLA-4
AND OTHER MOLECULES
The coinhibitory molecule CTLA-4 is constitutively expressed in
murine and human Tregs and exposed on the cell surface upon
activation (Read et al., 2000; Takahashi et al., 2000; Dieckmann
et al., 2001). A role for CTLA-4 in suppression in vivo has been
suggested, since CTLA-4 deﬁciency or blockade in mice results
in spontaneous autoimmunity, which can be ameliorated by Tregs
(Bachmann et al., 1999; Takahashi et al., 2000). In addition,CTLA-
4 blockade abrogates the protective effects of Tregs in murine
colitis models (Read et al., 2000). Also in vitro suppression of
murine Tcon proliferation (in the presence of APCs) was shown
to be abrogated in some studies by CTLA-4 blockage (Takahashi
et al., 2000; Tang et al., 2004). However, CTLA-4 deﬁcient Tregs
could still suppress through compensatory mechanisms involving
TGF-β and IL-10 in vitro and in vivo (Tang et al., 2004; Read et al.,
2006). Similarly, studies with human Tregs do not show a uni-
form picture: some in vitro studies did not ﬁnd an involvement
of CTLA-4 in Treg-mediated suppression of Tcon proliferation
(Baecher-Allan et al., 2001; Levings et al., 2001),while others could
partially abrogate suppressionbyCTLA-4blockage (Birebent et al.,
2004). These discrepancies may be explained by the involvement
of CTLA-4 in some but not all aspects of suppression. Our results
showed that rapid Treg-mediated suppression of cytokine tran-
scription in human Tcons was unaffected by CTLA-4 blockage,
irrespective of the presence or absence of APCs, while suppression
of proliferation in the presence of APCs was partially dependent
on CTLA-4 (Schmidt et al., 2011).
Regarding CTLA-4 blockade in long-term experiments, it has
to be considered that CTLA-4 is also expressed by activated Tcons
after 1–2 days of TCR stimulation (Walunas et al., 1994) and thus
cell-intrinsic negative signals are involved. These include compe-
tition with the costimulatory molecule CD28 for binding to the
B7 molecules CD80 (B7.1) and CD86 (B7.2; van der Merwe et al.,
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FIGURE 1 | Mechanisms ofTreg-mediatedTcon suppression.Tregs have
been described to suppressTcons by different mechanisms, depending on
the experimental setup, site and type of immune response. Tregs can
generate immunosuppressive adenosine or transfer cAMP toTcons.Tregs can
rapidly suppressTCR-induced Ca2+, NFAT, and NF-κB signaling. Tregs can also
produce immunosuppressive cytokines (IL-10, TGF-β, IL-35), and they can
suppress by IL-2 consumption or induce effector cell death via granzyme and
perforin. Furthermore, Tregs can suppressTcons indirectly by downregulating
costimulatory molecules on APCs (such as DCs) via CTLA-4. Details are
described in the text.
1997), transduction of negative signals that induce cell cycle arrest
and prevent IL-2 secretion (Krummel and Allison, 1996; Walunas
et al., 1996), and limiting T cell contact with APCs (Schneider
et al., 2006). Recently, the molecular mechanism of Treg-mediated
suppression via CTLA-4 was elucidated in more detail. Downreg-
ulation of CD80/CD86 expression on APCs by Tregs (Cederbom
et al., 2000) was shown to be partly dependent on CTLA-4 and
the adhesion molecule LFA-1, thereby indirectly inhibiting Tcon
activation by APCs in vitro (Oderup et al., 2006; Onishi et al.,
2008) and in vivo (Wing et al., 2008). Mechanistically, downreg-
ulation of CD80/CD86 on target cells by CTLA-4-expressing cells
can involve capture of these ligands by CTLA-4, a process called
trans-endocytosis (Qureshi et al., 2011). Another study supports
the importance of CTLA-4 in in vivo suppression without direct
effects on the responder T cells (Friedline et al., 2009). Strikingly,
micewithTreg-speciﬁc ablationof CTLA-4 spontaneously develop
fatal autoimmune disease (Wing et al., 2008), underlining the
importance of CTLA-4 expression on Tregs for the maintenance
of peripheral tolerance.
In contrast to the studies showing necessity of CTLA-4 for Treg-
mediated suppression,Tran et al. (2009) applied a mixed coculture
systemwithmurine andhumancells and showed that humanTregs
can suppress proliferation of murine Tcons by targeting murine
DCs through LFA-1:ICAM-1 interaction between Tregs and DCs.
Suppression was only evident in the presence of APCs, and it was
not abrogated when human CTLA-4 was blocked. Interestingly,
murine Tregs could not suppress human Tcons in the presence of
human APCs. These results argue for species-speciﬁc differences
in suppressive molecules, especially regarding CTLA-4.
Certain human and murine DC subsets express the enzyme
indoleamine 2,3-dioxygenase (IDO) that catalyzes degradation
of tryptophan to kynurenine, leading to starvation of effector T
cells and also to direct cell cycle arrest. At the same time, IDO
leads to iTreg generation (Fallarino et al., 2003, 2006; Curti et al.,
2007). Tregs themselves can, via CTLA-4-induced signaling, fur-
ther increase IDO expression in DCs. Additionally it was shown
that murine Tregs diminish glutathione synthesis in DCs, pre-
sumably CTLA-4-mediated, which leads to a redox environment
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unfavorable for Tcon proliferation (Yan et al., 2009, 2010). In con-
clusion, the importance of CTLA-4 in Treg-mediated suppression
is undisputed, but it does not seem to be the only suppressive
mechanism, and also species differences may exist. Importantly,
CTLA-4 blockage has already shown promising outcomes in clin-
ical trials for metastatic melanoma, presumably due to its effects
on both effector T cells and Tregs (Peggs et al., 2009). Despite
the prominent role for CTLA-4 in Treg-mediated inhibition of
DC activation, involvement of the costimulatory molecule CD40,
the deubiquitinase A20 acting as antigen-presentation attenua-
tor, and the surface receptor neuropilin-1 has also been described
(Hanig and Lutz, 2008; Sarris et al., 2008; Song et al., 2008). Fur-
ther, the adhesion molecule LAG-3 is expressed on Tregs, binds
to MHC class II molecules and was proposed to be involved in
suppression, since deﬁciency or blockage of LAG-3 resulted in dis-
turbance of T cell homeostasis in vivo and reduced suppressive
activity of Tregs in vitro (Huang et al., 2004; Workman and Vig-
nali, 2005). These effects might be mediated by LAG-3-induced
inhibition of DC activation (Liang et al., 2008). However, LAG-3
deﬁcient mice do not show signs of autoimmune disease. Further,
MHC class II expression on an activated human Treg subpopula-
tion that exerts rapid contact-dependent suppression seems to be
important (Baecher-Allan et al., 2006) as blockage of MHC class
II on activated Tregs was shown to abrogate suppression (Peiser
et al., 2007).
Tregs do not only reduce antigen presenting activity of APCs
but also support an immunosuppressive cytokine milieu by reduc-
ing IL-6while increasing IL-10productionbyDCs (Veldhoen et al.,
2006). In addition to these mechanisms, Tregs can inhibit Tcon
activation by reduction of contact formation between Tcons and
DCs (Tadokoro et al., 2006). As already mentioned, there is mutual
interplay between Tregs and tolerogenic DCs, the latter acting in
induction and expansion of Tregs.
SUPPRESSION VIA THE IMMUNOSUPPRESSIVE CYTOKINES
TGF-β, IL-10, AND IL-35
The role of immunosuppressive cytokines in Treg-mediated sup-
pression is still incompletely understood. Despite the importance
of TGF-β and IL-10 in several in vivo models, these cytokines
seem to be dispensable for other disease models such as autoim-
mune gastritis (Suri-Payer and Fritzsching, 2006) as well as for
most in vitro systems. Treg-mediated suppression via cytokines is
described in more detail below.
TGF-β
TGF-β1 deﬁcient mice develop T cell-mediated autoimmunity
within several weeks after birth (Li et al., 2006b). A similar pheno-
type is observed in mice lacking TGF-β responsiveness speciﬁcally
in T cells (Li et al., 2006a; Marie et al., 2006). Tregs can produce
high amounts of membrane-bound and soluble TGF-β, and block-
ing TGF-β partially abrogated suppression of T cell proliferation
in vitro using murine or human T cells (Nakamura et al., 2001,
2004; Levings et al., 2002), suggesting that Treg-produced TGF-
β controls autoimmunity. However, other groups did not ﬁnd
involvement of TGF-β in Treg-mediated suppression of T cells
(Baecher-Allan et al., 2002; Piccirillo et al., 2002; Godfrey et al.,
2005; Oberle et al., 2007). Although TGF-β deﬁcient Tregs could
suppress Tcon proliferation in vitro, TGF-β1 production by Tregs
was necessary to prevent colitis in several studies (Read et al., 2000;
Izcue et al., 2009). In addition, TGF-βRII knockout Tcons could
not be suppressed in vivo in colitis models, but TGF-β produced by
other cells than Tregs was likely involved in these models (Mamura
et al., 2004; Fahlen et al., 2005). Along that line, TGF-β produced
by DCs in the gut was critical to prevent colitis by Treg induc-
tion (Travis et al., 2007). Nevertheless, mice with T cell-speciﬁc
TGF-β1 deﬁciency showed enhanced Th1 and Th2 responses and
immunopathology including colitis, underscoring the importance
of T cell-producedTGF-β; however, thesemicewere resistant to the
induction of experimental autoimmune encephalitis (EAE) likely
due to impairedTh17 induction (Li et al., 2007). Therefore, the role
of TGF-β in Treg-mediated suppression might depend very much
on the type of effector cell and the site of the immune response, and
TGF-βmayevenpromoteproinﬂammatoryTh17 responses. Inter-
estingly, human Tregs could confer suppressive activity to target
Tcons in a cell-contact-dependent manner (so-called infectious
tolerance). Suppressive cells generated by infectious tolerance use
amechanism involvingTGF-β (Jonuleit et al., 2002).Amore recent
study shows that infectious tolerance in mice requires membrane-
bound TGF-β on Tregs (Andersson et al., 2008). Thus, TGF-β
function in vivo probably does not only involve direct suppression
of effector T cell signaling but also induction of Tregs, consis-
tent with lethal autoimmune disease and reduced peripheral Treg
numbers in TGF-β1 deﬁcient mice (Marie et al., 2005).
IL-10
The cytokine IL-10 exerts mainly immunosuppressive effects on
various cell types (Moore et al., 2001). IL-10 plays an impor-
tant role in Treg-mediated suppression of intestinal inﬂamma-
tion, since blocking IL-10 or using IL-10 deﬁcient Tregs abro-
gates the protective effect of Tregs on T cell transfer-induced
colitis (Asseman et al., 1999). Importantly, while the control of
memory/antigen-experienced T cells during prevention or cure
of colitis required IL-10, Treg-dependent prevention of naïve T
cell-mediated colitis does not require IL-10 (Asseman et al., 2003;
Uhlig et al., 2006), highlighting the involvement of different sup-
pression mechanisms depending on the activation status of the
target cell. The importance of IL-10 in Treg function in vivo
has been extended to infection and EAE models (McGeachy and
Anderton, 2005; Belkaid, 2007). Further, another study showed
that Treg-derived IL-10 is important for control of inﬂamma-
tion at environmental interfaces but seems to be dispensable for
control of systemic autoimmunity (Rubtsov et al., 2008). Along
that line, IL-10 or IL-10 receptor deﬁcient mice do not develop
autoimmunity, but are susceptible to colitis in the presence of
triggering ﬂora (Kuhn et al., 1993; Spencer et al., 1998). Impor-
tantly, the IL-10 locus was identiﬁed as a susceptibility locus in
ulcerative colitis (Franke et al., 2008), a form of human inﬂam-
matory bowel disease (IBD). Furthermore, IL-10RA or IL-10RB
mutations result in severe early onset IBD (Glocker et al., 2009).
Although IL-10 can suppress various immune cells including DCs,
direct effects of IL-10 on effector/memory T cells are important in
prevention of T cell-mediated colitis (Kamanaka et al., 2011). Two
recent studies further delineate that IL-10R signaling is needed in
Tregs as well as in Th17 cells in order to suppress colonic Th17
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responses (Chaudhry et al., 2011; Huber et al., 2011). Adding to
the complexity of IL-10 function in Treg-mediated suppression,
it was recently shown that Tregs need IL-10 (and not IL-35 and
TGF-β) to control IFN-γ production by T cells in the inﬂamed
skin, while IL-10 was dispensable for regulation of IFN-γ and T
cell expansion in the lymph node (Sojka and Fowell, 2011).
Of note, anti-inﬂammatory IL-10 might not be produced only
by T cells including Tregs and Foxp3− T regulatory 1 (Tr1) cells
(Roncarolo et al., 2006), but also by other cells such as regulatory
B cells (Mauri and Ehrenstein, 2008) and macrophages. The latter
were shown to indirectly inﬂuence suppression by acting on Tregs
to maintain Foxp3 (Murai et al., 2009).
IL-35
IL-35 is a recently discovered cytokine implicated inTreg-mediated
suppression and was shown to directly inhibit Tcon prolifera-
tion (Collison et al., 2007). Tregs deﬁcient in one of the IL-35
chains had reduced suppressive ability in vitro and in vivo in
an IBD model, although these mice did not show autoimmune
disease. In contrast to murine Tregs, human Tregs do not con-
stitutively express IL-35 (Bardel et al., 2008). Nevertheless, IL-35
may play a role also in human immunosuppression, as treatment
of naïve human or mouse T cells with IL-35 induced a so-called
iTR35 regulatory population that mediated suppression via IL-
35 but did not require IL-10, TGF-β, or Foxp3 (Collison et al.,
2010). These iTR35 were strongly suppressive in several in vivo
mouse models. Although naïve human Tregs did not express high
amounts of IL-35, long-term activation of human Tregs led to
upregulation of the IL-35 subunits starting at 3 days of activation
(Chaturvedi et al., 2011). These long-term activated Tregs exerted
contact-independent in vitro suppression in an IL-35-dependent
manner and also induced iTR35 cells. Thus, IL-35 may contribute
to infectious tolerance.
SUPPRESSION OF EFFECTOR CELLS BY IL-2 CONSUMPTION
AND APOPTOSIS INDUCTION
One efﬁcient way to repress immune responses would be killing
of effector cells by Tregs, which was indeed observed in certain
settings. It was shown that upon CD3/CD46 activation, human
nTregs express the serine protease granzyme (Gzm) A and kill
CD4+ T cells and other target cells in a perforin-dependent man-
ner, yet independent of the death receptor CD95 (Grossman et al.,
2004). In another report, contact-dependent suppression of Tcon
proliferation by activated murine Tregs in vitro was described to
be partially GzmB-dependent; however, in contrast to the results
of Grossman et al. perforin was not involved here (Gondek et al.,
2005).As suggested frommouse studies,GzmB-mediated suppres-
sion might be important in vivo to maintain transplant tolerance
(Gondek et al., 2008), but it might counteract tumor clearance by
killing tumor-reactiveNK cells andCD8+ T cells (Cao et al., 2007).
Involvement of the death receptor TRAIL in Treg-mediated sup-
pression of activated mouse Tcons was shown in vitro and in vivo
in a transplantation model, but required strong pre-activation of
Tcons and Tregs (Ren et al., 2007).
The importance of IL-2 consumption by Tregs due to their
high CD25 expression remains controversial. A study by Lenardo’s
group proposed that Tregs induce IL-2 deprivation-mediated
apoptosis in mouse Tcons, which was dependent on close
proximity between the cells (Pandiyan et al., 2007). However, the
authors did not observe suppression of IL-2 production during
the ﬁrst 48 h of coculture, which is not in line with many other
studies (Thornton and Shevach, 1998; Barthlott et al., 2005; Sojka
et al., 2005). Pandiyan et al. (2007) found that T cells deﬁcient in
the proapoptotic protein Bim could not be suppressed in vitro and
in vivo in a T cell transfer-induced IBD model. In contrast to these
results, a recent study by Vignali’s group did not ﬁnd involvement
of cell death induction by Tregs (Szymczak-Workman et al., 2011).
Szymczak-Workman et al. used responder Tcons that are resistant
to cytokine withdrawal-induced apoptosis due to Bim deﬁciency
or Bim/Puma double knockout or Bcl-2 overexpression and per-
formed in vitro and in vivo assays to conclude that Tregs do not
suppress via induction of apoptosis in responder Tcons. In addi-
tion to these mouse studies, we (Oberle et al., 2007) and others
(Vercoulen et al., 2009) also did not observe apoptosis induction
in human Tcons by human Tregs.
IL-2 does not only promote survival but also proliferation of
T cells, and IL-2 consumption seems to be involved in reducing
the positive effects of IL-2 on proliferation and IL-2 expression,
because exogenous IL-2 could abrogate Treg-mediated suppres-
sion of proliferation and/or of IL-2 production in vitro (Thornton
and Shevach, 1998; Baecher-Allan et al., 2001; de la Rosa et al.,
2004). However, during inhibition of murine Tcons by human
Tregs, IL-2 consumption was not causative for suppression of
proliferation, as blocking human CD25 did not abrogate sup-
pression under optimal stimulation conditions for the human
Tregs (Tran et al., 2009). Of note, under suboptimal stimulation
conditions, human Tregs required CD25 signals in order to be
functionally suppressive, yet the suppression mechanism under
these conditions remains elusive and may or may not involve
IL-2 consumption (Tran et al., 2009). We found that, although
exogenous IL-2 partially abrogated suppression of human Tcon
proliferation by human Tregs, rapid suppression of IL-2 tran-
scription by human pre-activated Tregs was not affected (Oberle
et al., 2007), which argues for different suppression mechanisms
for proliferation and cytokine transcription. Here, IL-2 itself led
to increased IL-2 mRNA expression (Oberle et al., 2007), however,
for later time points, negative feedback of IL-2 on IL-2 mRNA and
protein expression was described (Villarino et al., 2007). These
differences in the effect of IL-2 on IL-2 expression may depend on
time point, species, amount of IL-2 and cellular activation status
and may contribute to the inconsistent results on the role of IL-
2 consumption in Treg-mediated suppression. Together, the role
of IL-2 consumption remains controversial and may depend on
the speciﬁc setting and stimulation conditions of the Tregs. IL-2
consumption by Tregs may even enhance certain effector T cell
reactions, which was shown for Th17 responses (Pandiyan et al.,
2011). In addition, the link of IL-2 consumption to apoptosis is
unclear, as exogenous IL-2 could rescue proliferationof suppressed
human Tcons without reducing background apoptosis (Vercoulen
et al., 2009).
Together, it can be concluded from these studies that IL-2
consumption by Tregs and apoptosis induction in suppressed
target cells may only play a role in suppression under certain
circumstances.
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SUPPRESSION VIA EXPRESSION OF EFFECTOR T
CELL-SPECIFIC TRANSCRIPTION FACTORS
Tregs may be specialized to suppress a certain CD4+ T cell subset
in particular by expression of the hallmark transcription factor of
this very subset. In this regard, it was shown that a Treg subset
upregulated T-bet in response to IFN-γ, which was essential for
the control of Th1-mediated inﬂammation (Koch et al., 2009).
Similarly, IRF-4 (which is typically made by Th2 and Th17 cells)
expression in Tregs was required for suppression of Th2 responses
(Zheng et al., 2009). Moreover, expression of STAT3 (which drives
Th17 differentiation) in Tregs was increased and crucial during
control of Th17-mediated intestinal pathology (Chaudhry et al.,
2009). Adding to that list, loss of the Th2-associated transcrip-
tion factor GATA-3 in Tregs led to autoimmune disease, in that
case accompanied by destabilization of Foxp3 expression and ele-
vated Th1, Th2, and Th17 cytokine levels (Wang et al., 2011).
GATA-3 deﬁcient Tregs tended to convert into a Th17 pheno-
type, and it was further shown that GATA-3 was upregulated upon
stimulation in murine as well as human Tregs (Wohlfert et al.,
2011). However, the mechanism through which Tregs suppress via
expression of effector T cell-speciﬁc transcription factors is cur-
rently unclear but might involve competition for limiting factors.
The transcription factors could directly interact with Foxp3, as
described for IRF-4, STAT3, and RORγt. Expression of the effec-
tor T cell-speciﬁc transcription factors and their regulated genes
such as chemokine receptors might also enable Tregs to migrate
to and proliferate at the site of immune response. Accordingly,
suppressor activity of IRF-4 or STAT3 knockout Tregs in vitro was
shown to be unimpaired, and GATA-3 was selectively expressed by
Tregs at environmental interfaces.
In contrast, expression or activation of Th-speciﬁc transcrip-
tion factors in Tregs might lead to a loss of Foxp3 expression and
suppressive function. For example, STAT3 was described to medi-
ate downregulation of Foxp3, and intriguingly, STAT3 is activated
by several cytokines which negatively regulate Tregs and Foxp3,
such as IL-6, IL-23, or IL-27 (Yang et al., 2007, 2008; Yao et al.,
2007; Huber et al., 2008; Ahern et al., 2010). Thus, loss of STAT3
expression in T cells during T cell transfer-induced colitis and
systemic inﬂammation increased Treg induction and ameliorated
disease (Durant et al., 2010).
Plasticity between CD4+ T cell subsets might be higher than
originally anticipated, although the stability of the Treg lineage
in vivo is highly controversial (Zhou et al., 2009; Rubtsov et al.,
2010). Yet several lines of evidence indicate that plasticity is par-
ticularly pronounced between Th17 cells and iTregs (Lee et al.,
2009), and an intermediate state with expression of both RORγt
and Foxp3 at the same time was observed (Lochner et al., 2008;
Zhou et al., 2008). In certain cytokine milieus, even induction of
IL-17 was described in murine and human Tregs, which might
retain suppressive function (Xu et al., 2007; Koenen et al., 2008;
Osorio et al., 2008; Beriou et al., 2009; Voo et al., 2009).
ADENOSINE AS IMMUNOSUPPRESSIVE MOLECULE
Hydrolysis of extracellularATP toADP orAMP by the ectoenzyme
CD39, expressed by all murine Tregs and by about 50% of human
Tregs, represents anotherTreg-mediated anti-inﬂammatorymech-
anism (Borsellino et al., 2007). CD39 knockout Tregs showed
reduced suppressive capacities in vitro and in vivo (Deaglio et al.,
2007). In human Tregs, CD39 expression was suggested to identify
a highly suppressive Treg subset (Mandapathil et al., 2009), and
suppression of Tcon proliferation by this subset could be partially
abrogated by blockage of ectonucleotidase activity (Mandapathil
et al., 2010). CD73, also expressed by Tregs, further degrades AMP
to adenosine (Kobie et al., 2006). Adenosine signals via the A2A
adenosine receptor and may inhibit DCs as well as activated T
cells, e.g., by elevation of cyclic AMP (cAMP; Ernst et al., 2010).
In human but not mouse T cells, ATP can also directly increase
cAMP levels through the P2Y11 receptor (Abbracchio et al., 2006).
In vivo, A2A receptor signaling might induce anergy and promote
iTreg generation (Zarek et al., 2008). In conclusion, generation of
adenosine seems to be important for the suppressive function of
certain Treg subsets.
SUPPRESSION VIA cAMP, ICER, AND NFAT
Tregs produce high levels of cAMP and cAMP amounts were
shown to rise in suppressed Tcons upon contact with Tregs, pre-
sumably via transfer through gap junctions from murine Tregs to
Tcons (Bopp et al., 2007). Accumulation of high cAMP amounts
in Tregs might require Treg pre-activation (Bazhin et al., 2010).
cAMP seems to be an important component of Treg-mediated
suppression, since suppression of IL-2 transcription and prolifer-
ation could be partly abrogated by a cAMP antagonist or a gap
junction inhibitor (Bopp et al., 2007). The same group recently
also showed that induction of cAMP in murine DCs upon Treg
coculture contributes to suppression of DCs (Fassbender et al.,
2010). The authors suggest that in suppressed Tcons, cAMP acts by
inducing expression of the inducible cAMPearly repressor (ICER),
which functions as a repressor, e.g., at the IL-2 and IL-4 gene loci
(Bodor et al., 2000). ICER protein and mRNA were previously
shown to be increased in suppressed mouse T cells after 17–20 h
of Tcon:Treg coculture stimulation (Bodor et al., 2007a) which
correlated with an increase in cAMP (Bopp et al., 2007). In these
studies, an increase in ICER and cAMP was not yet detectable
after 4–5 h. In human Tcons, we also did not observe ICER upreg-
ulation upon coculture with Tregs compared to coculture with
Tcons within 5 h (Oberle et al., 2007; Oberle and Schmidt, unpub-
lished data). Since NFAT1/4 double knockout Tcons cannot be
fully suppressed by Tregs in long-term suppression assays, such
as proliferation or IL-2 mRNA and protein expression after 18 h
(Bopp et al., 2005), it was proposed that NFAT forms inhibitory
complexes on cytokine promoters with transcriptional repressors
such as ICER, PPRγ, or p21SNFT (Bandyopadhyay et al., 2007;
Bodor et al., 2007a,b). However, by calculating the percentage of
suppression, partial inhibition can be observed although NFAT1/4
double knockout T cells display hyperproduction of IL-2, suggest-
ing that NFAT1/4 double knockout Tcons are less susceptible, but
not completely resistant to Treg-mediated suppression. Further-
more, although ICER failed to accumulate in suppression assays
with B7 deﬁcient responder T cells (as ICER induction in sup-
pressed T cells was CTLA-4/B7 and GITR-dependent), residual
suppression was still detectable (Bodor et al., 2007a). These results
argue for additional suppressive mechanisms together with those
mediated by CTLA-4 and ICER:NFAT. More recently, it was pro-
posed that NFAT2 together with ICER translocates to the nucleus
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to confer repression of the IL-2 promoter in murine T cells upon
coculture with Tregs (Vaeth et al., 2011). However, depending on
the experimental setting, either increased or decreased NFAT2
nuclear translocation was observed in suppressed compared to
control mouse T cells, while ICER clearly translocated into the
nucleus upon Treg-mediated suppression (Vaeth et al., 2011).
Together with a report showing that Cbl-b deﬁcient T cells
are less sensitive to suppression by Tregs (Wohlfert et al., 2004),
data on inhibitory NFAT complexes imply that Treg-suppressed
Tcons display features of anergy, as both NFAT1 and Cbl-b are
crucial in anergy induction (Macian et al., 2002; Soto-Nieves et al.,
2009). Anergy induction in suppressed Tcons might occur later
than inhibition of cytokine transcription since we did not detect
accumulation of ICER mRNA or other anergy-related genes up
to 5 h after TCR stimulation in suppressed compared to control
human Tcons (Oberle et al., 2007). By comparing gene expression
of suppressed and anergized murine Tcons, Sukiennicki and Fow-
ell (2006) found only partial overlap of NFAT-dependent gene
expression while most genes did not overlap. However in their
study, changes in gene expression were not yet pronounced 12 h
after coculture, but only evident after 36 h. This is in contrast
to the gene array performed with human T cells in our group,
in which, e.g., NFAT and NF-κB target genes were already sup-
pressed in human Tcons within 1.5–3 h of coculture; however, this
gene array was performed with pre-activated Tregs (Schmidt et al.,
2011). Thus, discrepancies may be due to Treg pre-activation or
species.
In contrast to its role in anergy induction, NFAT also plays an
important activating role in TCR-induced transcription of T cell
effector cytokines. This rapid TCR-induced NFAT activation in
Tcons is suppressed by Tregs, which will be described in the next
section.
RAPID SUPPRESSION OF TCR-INDUCED CALCIUM, NFAT
AND NF-κB SIGNALING AND CONSEQUENTLY CYTOKINE
TRANSCRIPTION IN Tcons UPON SUPPRESSION BY Tregs
Signaling events and in particular TCR signaling in responder
Tcons upon suppression by Tregs has not been studied exten-
sively so far. Yet detailed knowledge might be important for
therapeutic interventions in certain T cell-mediated diseases, as
resistance of effector T cells to Treg-mediated suppression fre-
quently occurs in autoimmune diseases (Buckner, 2010).However,
kinetics of cytokine suppression has been analyzed in detail. Our
group previously showed that inhibition of cytokine transcription
occurs rapidly within 1–3 h (Oberle et al., 2007). This suppres-
sion of cytokine transcription was also observed when stronger
TCR/CD28 stimulation was applied and occurred within 30–
45min when pre-activated Tregs were used (Schmidt et al., 2011).
Thornton and Shevach (1998) showed potent inhibition of IL-2
mRNA production in murine Tcons by Tregs, though the authors
did not analyze earlier than 15 h. Further experimentswithmurine
Tcon:Treg cocultures showed that IL-2 mRNA suppression starts
between 5 and 6 h of coculture stimulation (Barthlott et al., 2005)
or even later, after 6–12 h (Sojka et al., 2005). In a subsequent
paper, the latter group did not observe IL-2 mRNA suppression
after 12 h of coculture (Sukiennicki and Fowell, 2006). In contrast
to our experiments, these studies were conducted in the presence
of APCs and with murine T cells. Thus, discrepancies in IL-2
mRNA suppression kinetics might be due to species differences
or experimental setup regarding strength of stimulation and pres-
ence of APCs. There may also be differences in responder Tcon
susceptibility to suppression, which could be inﬂuenced by the
cell puriﬁcation procedure and resting time between puriﬁcation
and initiation of cocultures. In addition, we used pre-activated
Tregs, while the others did not. Nevertheless, when Sojka et al.
used pre-activated Tregs, they still observed suppression of IL-2
secretors not earlier than 4–6 h after initiation of coculture. How-
ever, at earlier points in time, the induction of IL-2 also was still
very low (Sojka et al., 2005).
To analyze Treg-mediated effects on Tcons, we favored an
in vitro cell culture system without APCs. Thus, we could analyze
direct effects of Tregs on Tcons and we obtained pure populations
of responder Tcons after coculture. However, it is still a matter
of debate whether the main targets of Treg-mediated suppres-
sion in vivo are T cells or rather APCs. It remains possible that
Tregs utilize distinct mechanisms to directly suppress Tcons or
APCs, and both mechanisms might play a role in vivo. Although
several studies have shown that murine as well as human Tregs
inhibit TCR-induced proliferation of Tcons in the absence of
APCs (Dieckmann et al., 2001; Ermann et al., 2001), others found
that murine Tregs fail to inhibit Tcons stimulated by anti-CD3
antibodies (Thornton and Shevach, 2000). In general, signiﬁcant
suppression in the absence of APCs is mostly observed at high
(1:1) Treg to Tcon ratios, which makes cell density very impor-
tant to control. Nevertheless, as APC-containing cocultures may
represent a more physiological setting than Tcon:Treg cocultures
without APCs, we also used another in vitro cell culture system to
show that rapid suppression of cytokine transcription can occur
in the presence of APCs (Schmidt et al., 2011).
Transcription of several effector T cell cytokines is initiated
upon TCR stimulation and costimulation by the cognate antigenic
peptide presented on a mature APC or, artiﬁcially, by agonistic
anti-CD3 and anti-CD28 antibodies. As we observed rapid sup-
pression of cytokine transcription, we questioned whether Tregs
directly inﬂuence TCR signaling. Until recently, there was no
comprehensive study on TCR signaling events in Tcons upon sup-
pression by Tregs. TCR stimulation leads to a cascade of protein
phosphorylation and dephosphorylation events, which ultimately
activates transcription factors to initiate a distinct transcriptional
program (Lin and Weiss, 2001; Smith-Garvin et al., 2009). The
most important transcription factors for the induction of cytokine
expression are NF-κB, NFAT, and AP-1, which together mediate
activation of several cytokine genes, e.g., IL-2 and IFN-γ (Jain
et al., 1995; Young, 1996; Sica et al., 1997). Before we describe our
results regarding TCR signaling in Treg-suppressed Tcons, we will
give a brief introduction into TCR signaling.
OVERVIEW: TCR SIGNALING
Activation of the NF-κB, NFAT, and AP-1 signaling pathways
starts with TCR stimulation-induced phosphorylation of TCR-
associated CD3 chains by the Src family kinases Fyn and Lck,
leading to binding of ZAP-70. ZAP-70 phosphorylates the adapter
protein LAT, which is critical for recruitment of important signal-
ing proteins, leading to activation of Phospholipase Cγ1 (PLCγ1;
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Qi and August, 2007). Active PLCγ1 cleaves phosphatidylinosi-
tol 4,5-bisphosphate (PIP2) to generate the second messengers
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG
mediates its effects via membrane recruitment and, thus, activa-
tion of signaling proteins, whereas IP3 induces calcium (Ca2+)
inﬂux into the cytosol. Activation of both NF-κB and NFAT
requires the activity of PLCγ1, while the AP-1 pathway is largely
PLCγ1-independent. These signaling pathways are summarized
in Figure 2 and will be described in more detail, although still
simpliﬁed, below.
Ca2+ signaling
Themain pathway to initiate aCa2+ signal in T cells is via IP3 bind-
ing to IP3 receptors (IP3Rs) in the endoplasmatic reticulum (ER)
membrane, which leads to release of Ca2+ from the ER into the
cytoplasm. Depletion of the ER Ca2+ store induces Ca2+ inﬂux
from outside the cell by a process called store-operated calcium
entry (SOCE). The stromal interaction molecule (STIM) senses
ER Ca2+ store depletion and in turn triggers opening of cal-
cium release-activated calcium (CRAC) channels in the plasma
membrane, leading to Ca2+ entry from the extracellular space
into the cytoplasm (Quintana et al., 2005; Feske, 2007).
T cells express three types of IP3Rs to varying degrees depend-
ing on their stage of differentiation (Grafton andThwaite, 2001). It
is not clear which IP3R is the most important receptor in periph-
eral T cells, and knowledge of regulation of these receptors by
molecules other than IP3 is very limited. IP3-mediated Ca2+ store
depletion appears to be the main mode of Ca2+ entry in lym-
phocytes (Oh-Hora and Rao, 2008). However, Ca2+ release from
intracellular stores can be initiated not only by IP3, but cyclic ADP
ribose (cADPR) seems to be important for long-lasting release of
Ca2+ from stores (Guse et al., 1999; Schwarzmann et al., 2002).
Further, nicotinic acid adenine dinucleotide phosphate (NAADP)
was described to act prior to IP3 and cADPR to provide sufﬁcient
Ca2+ amounts to sensitize IP3Rs (Gasser et al., 2006). Regarding
plasma membrane Ca2+ channels, there is evidence that CRAC
channels are most critical for TCR signal transduction (Feske et al.,
2005), but the L-type voltage-gated Ca2+ channel CaV1.4 also
seems to be important for TCR signaling and T cell homeostasis
(Omilusik et al., 2011). STIM1 seems to be the predominant player
FIGURE 2 | Simplified view of TCR signaling inT cells. After TCR
stimulation, several pathways are initiated which ultimately result in T cell
activation, proliferation and expression of cytokines such as IL-2 and IFN-γ.
The main transcription factors involved are AP-1, NFAT, and NF-κB. AP-1 is
activated by a MAPK cascade. NF-κB is activated by PKCθ-dependent
activation of the IKK complex and subsequent IκB degradation, and Ca2+ also
contributes to NF-κB activation. NFAT is activated by Ca2+ inﬂux which
activates the NFAT-dephosphorylating phosphatase calcineurin. Only the
major pathways are displayed here and represent a simpliﬁed view of TCR
signaling. Details are described in the text.
Frontiers in Immunology | T Cell Biology March 2012 | Volume 3 | Article 51 | 8
Schmidt et al. Signaling in Treg-suppressedT cells
of SOCE in T cells although both STIM1 and STIM2 can recon-
stitute SOCE in STIM1 deﬁcient T cells (Oh-Hora et al., 2008).
However, STIM1 as well as STIM2 knockout T cells show severely
impaired Ca2+ entry, impaired NFAT activation and cytokine pro-
duction. Of note, these cells can still proliferate in vivo (Oh-Hora
et al., 2008). Interestingly STIM1, which is very abundant in lym-
phocytes but not in excitable cells, inhibits voltage-gated CaV1.2
channels while it activates the CRAC constituent ORAI (Park et al.,
2010; Wang et al., 2010).
NFAT activation
NFAT activation in T cells is dependent on the generation of
a Ca2+ signal, which activates the Ca2+:calmodulin-dependent
phosphatase calcineurin. Calcineurin dephosphorylates NFAT,
thus unmasking its nuclear localization sequence and enabling
transport of NFAT into the nucleus. The NFAT family consists
of ﬁve members, three of which are expressed by T cells: NFAT1
(also called NFATp or NFATc2), NFAT2 (NFATc or NFATc1), and
NFAT4 (NFATx or NFATc3; Macian, 2005), and each of them
appears in several isoforms. The constitutively expressed NFAT1
represents the main NFAT isoform in resting T cells (Macian et al.,
2002). Although NFAT can act as a transcription factor alone or
in homodimers, many transcription factors interact with NFAT
to activate or inhibit transcription, amongst them AP-1. Various
cytokine promoters, e.g., IL-2, IL-4, IL-5, IFN-γ, and TNF-α con-
tain cooperative NFAT:AP-1 binding sites which greatly enhance
transcription of the respective cytokine (Rao et al., 1997;Chinenov
and Kerppola, 2001; Macian et al., 2001; Hermann-Kleiter and
Baier, 2010). Of note, AP-1 binding to the IL-2 promoter becomes
undetectable in the absence of NFAT (Jain et al., 1993). Interest-
ingly, it could be shown that differences in Ca2+ inﬂux change the
number of IL-2 expressing human CD4+ T cells rather than the
amount of IL-2 expression per cell, suggesting an all-or-nothing
response in Ca2+-induced IL-2 (and IFN-γ) production. NFAT
was identiﬁed as themolecular switch being either in or outside the
nucleus, while nuclear translocation of NF-κB and expression of
exclusiveNF-κB target genes was graded (Podtschaske et al., 2007).
NF-κB activation
In resting T cells, the NF-κB heterodimer is associated with the
cytosolic inhibitor of κB(IκB),whichmasks its nuclear localization
sequence (Vallabhapurapu and Karin, 2009). Several NF-κB and
IκB family members exist, from which the p65:p50:IκBα complex
is the most prominent NF-κB:IκB complex in T cells. After TCR
triggering, DAG is important for localization and, thus, activation
of PKCθ (Isakov and Altman, 2002). PKCθ activates the NF-κB
pathway by modulation of the CARMA1:Bcl-10:MALT1 (CBM)
complex, which then activates the trimeric IKK complex compris-
ing the catalytic subunits IKKα and IKKβ as well as the regulatory
subunit IKKγ. The catalytic subunits of the active IKK complex
phosphorylate IκBα, leading to IκBα polyubiquitination and sub-
sequently its proteasomal degradation, allowing for translocation
of NF-κB to the nucleus. Importantly, NF-κB activation is also
inﬂuenced by Ca2+ (see below).
The NF-κB complex itself can be phosphorylated and acety-
lated, which regulates its transcriptional activity and association
with other transcription factors (Li and Verma, 2002; Perkins,
2006). For example, phosphorylation of p65 on serine (Ser)529
and Ser536 in its transactivation domain by IKKβ may enhance
activity (Sakurai et al., 1999).
The AP-1 pathway
The AP-1 pathway is initiated by a MAPK cascade leading to acti-
vation of MAPKs, such as ERK, JNK, and p38 (Dong et al., 2002).
LAT recruits certain proteins,which are important for MAPK acti-
vation via Ras and Rac. Recent data led to the assumption that in
T cells, p38 is not only activated by the classical MAPK cascade
but also, and primarily, via an alternative pathway characterized
by direct phosphorylation of p38 by ZAP-70 and subsequent
p38 autophosphorylation (Mittelstadt et al., 2009). MAPKs pro-
mote expression, phosphorylation, and activation of Fos and Jun,
which together comprise the AP-1 transcription factor (Johnson
and Lapadat, 2002). In contrast to NF-κB and NFAT, the AP-1
pathway is largely independent of PLCγ, but DAG can enhance
Ras recruitment and activation and, thus, ERK1/2 signaling. In
addition, calcineurin can contribute to JNK activation (Werlen
et al., 1998), however, JNK1/2 seem to be dispensable for primary
activation and IL-2 production of T cells (Sabapathy et al., 2001).
TCR SIGNALING IN Tcons UPON Treg-MEDIATED SUPPRESSION
Previously, our group showed that rapid suppression of Th1
cytokine transcription in human Tcons by Tregs occurs immedi-
ately after induction of mRNA transcription (Oberle et al., 2007).
The suppression mechanism was independent of TGF-β and IL-
10, IL-2 consumption, initiation of apoptosis, and induction of
anergy-related genes in suppressed Tcons. As Tcon inhibition was
detected very rapidly, we asked whether Tregs may directly dis-
rupt key components of TCR signaling which could impede Tcon
cytokine transcription and, consequently, Tcon function. Indeed,
our recent data show that pre-activated human Tregs rapidly sup-
pressed TCR-induced signaling events in Tcons (Schmidt et al.,
2011). In detail, TCR-induced Ca2+ release from intracellular
stores and, consequently, Ca2+ inﬂux was blocked immediately
after TCR stimulation in suppressed Tcons. Inhibition of Ca2+
signals resulted in decreased NFAT1 dephosphorylation and NFAT
target gene expression.AlsoNF-κB activation, as detected by phos-
phorylation of IKK, IκBα, and p65 aswell as target gene expression,
was strongly and rapidly inhibited. Ca2+ suppression appears to be
causative for suppressionof NFAT,NF-κB,and IL-2, as suppression
of either one could be abrogated by artiﬁcial Ca2+ store deple-
tion. In contrast, Ca2+-independent events such as TCR-proximal
signaling and the AP-1 pathway were not affected in suppressed
Tcons. Interestingly, PLCγ1 phosphorylation as well as IP3 genera-
tion were not altered in suppressed Tcons. Therefore, Tregs inhibit
Ca2+ store depletion in Tcons via so far unknown mechanisms.
A summary of these results is shown in Figure 3 and discussed
in more detail below.
TCR-proximal and AP-1 signaling
To our knowledge, there are no studies regarding phosphorylation
of TCR signaling molecules in CD4+ Tcons upon suppression
by Tregs. An approach using human CD8+ T cells demonstrated
that CD3ζ and ZAP-70 phosphorylation was unaffected by Tregs,
though activation of ERK was inhibited (Baatar et al., 2009). In
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FIGURE 3 |Tregs suppress particularTCR signaling pathways in
Tcons. ActivatedTregs rapidly suppress cytokine expression in Tcons
via inhibition of Ca2+ signals and consequently reduced NF-κB and
NFAT activation. Suppression byTregs requires at least 30min of
coculture, is favored by cell contact and sustained after Treg removal.
Red indicates Treg-mediated suppression of TCR-induced activation in
Tcons. Molecules displayed in green were not inhibited during
Treg-mediated rapid suppression of cytokine transcription. Molecules
in gray were not analyzed or TCR-induced activation was not
detectable.
contrast, during rapid suppression of CD4+ Tcons,we did not ﬁnd
inhibition of the AP-1 pathway. This discrepancy might be due to
differences between CD4+ and CD8+ T cells or to the coculture
setup as Baatar et al. used non-pre-activated Tregs and cocultures
were set up 6 h before stimulation.
Suppression of calcium signaling in Tcons
At ﬁrst glance, our results seem to be in contrast with two other
studies which claim that Tregs do not inhibit initial TCR sig-
naling in target T cells. However, the experimental setup differs.
Tang and Krummel (2006) analyzed TCR-induced Ca2+ signals in
suppressed murine T cells in contact with freshly isolated Tregs
by microscopic Ca2+ measurements. The authors used a TCR-
transgenic system and stimulated with peptide-pulsed B cells.
They did not observe suppression of Ca2+ signals in Tcons and
concluded thatTregs donot inﬂuenceTCR-proximal andCa2+ sig-
naling. However, using non-pre-activated Tregs,Ca2+ suppression
may not be detectable as Tregs might not be sufﬁciently acti-
vated within the short time period of these experiments to obtain
suppressive capacities (unpublished observation). In addition,
species differences might account for the discrepancy between
these results and ours. Another study found that sustained Ca2+
increase in human T helper cells was not affected by Tregs when
they were stimulated with superantigen-pulsed B cells (Esquerre
et al., 2008). A main difference between these experiments and
ours is that the authors explored the effect of expanded Tregs on
the effector phase of the immune response and, thus, as target
cells they used pre-activated T helper cells which were expanded
at least 14 days in vitro. These cells might be less susceptible to
Treg-mediated Ca2+ suppression and/or more reactive to stim-
ulation than resting CD4+CD25− Tcons as used in our study.
In addition, stimulation by superantigen-pulsed B cells might
be stronger than the anti-CD3/anti-CD28 antibody stimulation
used by us. As the authors do not provide data on the initial
stimulation-induced increase in Ca2+ concentrations in T helper
cells but focus on the sustained Ca2+ signal, it cannot be discussed
whether Tregs would inﬂuence the initial increase in Ca2+ imme-
diately after being stimulated by the APC, as we observe for Tcons
stimulated with crosslinked anti-CD3/anti-CD28 antibodies. Of
note, we also detected rapid suppression of NF-κB signaling and
IL-2 transcription when we used APCs plus anti-CD3 antibod-
ies for stimulation, although we did not perform Ca2+ analyses
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in this setting. Interestingly, Esquerre et al. found that human
Tregs (which were in vitro expanded for at least 14 days) inhibited
polarization of T helper cell IFN-γ toward the APC in a TGF-β-
dependent manner, while inhibition of proliferation and IFN-γ
production was not affected by TGF-β blocking. Together, these
data again emphazise that Tregs seem to employ different mech-
anisms of suppression, depending on the activation state of the
Tregs themselves as well as of the responder T cells and suggest
differences in inhibition of priming versus inhibition of effector
function.
We found that Tregs inhibited Ca2+ signaling without involve-
ment of TCR-proximal signaling molecules, including PLCγ1.
Similarly, a report by Gri et al. (2008) shows Treg-mediated
suppression of Ca2+ signals in murine mast cells in a PLCγ2-
independent fashion. However, suppression of Ca2+ signals in
mast cells did not affect Ca2+ store depletion but rather involved a
cAMP-dependent suppression of Ca2+ inﬂux through the plasma
membrane. The authors proposed that cAMPalters themembrane
potential through unknown mechanisms and decreases perme-
ability of Ca2+ channels, as demonstrated formast cells previously.
This suppression was dependent on interaction of OX40 on Tregs
with OX40L on mast cells. In our setup,OX40 is likely not involved
since OX40L is not expressed by T cells, but mainly by APCs.
Though suppression of Ca2+ signals might be a general mech-
anism of Treg action, we describe a cAMP-independent rapid
suppression of Ca2+ store depletion in human T cells. This Ca2+
suppression resulted in immediate inhibition of NF-κB and NFAT
activation and, consequently, IL-2 transcription. However, we still
observed a late effect with a cAMP antagonist on IL-2 mRNA
suppression upon stimulation for approximately 5 h (unpublished
observation), which is in line with results by others using murine
Tcons (Bopp et al., 2007). Interestingly, we found that IFN-γ
suppression was not affected by the cAMP antagonist (unpub-
lished observation). In general, suppression mechanisms might
be diverse regarding different cytokines, e.g., by the inﬂuence of
promoter-speciﬁc repressors such as ICER.
The exact mechanism through which Tregs inhibit Ca2+ store
depletion in Tcons remains elusive. Since IP3 amounts were unal-
tered, IP3 metabolism seems unchanged. Treg pre-activation was
required to observe this rapid suppression, yet it is unknownwhich
molecular changes take place in Tregs during pre-activation. Fur-
thermore, the receptor for Tregs on Tcons remains elusive; how-
ever, our results indicate that triggering of this unknown receptor
must lead to a suppressive signal within approximately 30min. It
is tempting to speculate that this rapid process involves signaling
via phosphatases or kinases in Tcons. Suppression might involve
yet unknown modiﬁcations of the IP3R which hinder its inter-
action with IP3. Future studies will be needed to address these
questions and decipher the mechanism how Tregs inhibit Ca2+
signals in Tcons. In addition, it would be interesting to analyze
potential differences in Ca2+ suppression when distinct Treg sub-
sets are used. Further, there may be differences in suppression of
diverse target T cell types. Although Tregs can suppress Th1, Th2,
and Th17 cytokines, one could speculate that Ca2+ suppression
may be irrelevant for Th17 suppression, since IP3R-mediatedCa2+
release is needed for initial IL-2 and IFN-γ production, but nega-
tively regulates IL-17 production (Nagaleekar et al., 2008).Of note,
several studies found that Th17 cells tend to be refractory to Treg-
mediated suppression (Stummvoll et al., 2008; Chauhan et al.,
2009; Vercoulen et al., 2009), although the underlying mechanism
remains to be investigated.
NFAT1 suppression
In addition to the rapid suppression of NFAT1 dephosphory-
lation we described, it is possible that after several hours of
Treg:Tcon interaction, NFAT also exerts a repressive role by form-
ing inhibitory complexes with other transcription factors on
cytokine promoters, as described for NFAT:ICER complexes. Dif-
ferent roles of NFAT depending on the experimental readout
are also implied by data from Vaeth et al. (2011) who observed
increased NFAT2 nuclear translocation upon contact to Tregs in
an adoptive T cell transfer model while in an in vitro coculture
assay of murine Tcons and Tregs in the presence of APCs, they
show decreased NFAT2 nuclear translocation. The latter result
corresponds to our data for human NFAT1. Vaeth et al. analyzed
NFAT2/ICER translocation not earlier than 24 h after stimulation.
We could not detect NFAT2 in primary human Tcons upon short-
term stimulation (unpublished observation), in line with reports
describing that NFAT2/αA, the most prominent NFAT2 isoform in
peripheral T cells, is only weakly expressed in the naïve state and
induced following CD3/CD28 stimulation (Serﬂing et al., 2006).
In conclusion, NFAT2:ICER complexes may play a role in sup-
pression of pre-activated T cells or within long-term suppression
assays, but do not seem to be involved in resting T cells. In addi-
tion, other NFAT family members may have a dual role in early
versus late suppression mechanisms.
Suppression of NF-κB signaling in Tcons downstream of PKCθ
To our knowledge, except for our report (Schmidt et al., 2011)
there are no publications comparing IKK and IκBα phosphory-
lation or NF-κB activation in suppressed and control Tcons. Yet
one study showed that Tregs inhibit TLR-induced NF-κB activa-
tion in murine macrophages, suggesting suppression of NF-κB as
a common mechanism of Treg-mediated suppression (Li et al.,
2010). However, Li et al. cannot exclude that NF-κB suppression is
a secondary effect due to increased IL-10 and TGF-β levels in the
suppressed macrophages.
As artiﬁcial Ca2+ store depletion could abrogate Treg-mediated
suppression, we hypothesize that suppression of Ca2+ signals
causes suppression of NF-κB. However, the exact mechanism
through which Ca2+ inﬂuences NF-κB in T cells and how Tregs
interfere here remains to be resolved. Calcineurin, which is acti-
vated by Ca2+, synergistically contributes to degradation of IκBα
when PKCθ is active (Frantz et al., 1994; Feske, 2007). As shown
in Jurkat and primary T cells, this effect is probably due to acti-
vation of IKKβ by calcineurin and PKCθ (Trushin et al., 1999).
The effects of Ca2+ on the CBM complex are less clear and
involve positive as well as negative regulation. On the one hand,
the Ca2+:calmodulin-dependent kinase CaMKII was shown to
enhanceNF-κBactivationbyphosphorylationof CARMA1 (Ishig-
uro et al., 2006) and Bcl-10 (Oruganti et al., 2011). Furthermore,
calcineurin was recently reported to enhance CBM complex for-
mation by dephosphorylation of Bcl-10 [at (a) different phospho-
site(s)] (Frischbutter et al., 2011; Palkowitsch et al., 2011). On
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the other hand, Ca2+:calmodulin binding to Bcl-10 was shown to
reduce association of Bcl-10 with CARMA1 (Edin et al., 2010).
Interestingly, we have indications pointing to an unknown and
calcineurin-independent role for IKK in rapid TCR-mediated and
Ca2+-dependent NF-κB activation. In Tcons which were treated
with the calcineurin inhibitor cyclosporin A, NFAT activation
could be completely abrogatedwhile IKKphosphorylationwas not
and IκBα phosphorylation was only slightly affected (unpublished
observation). In contrast, when we treated Tcons with the Ca2+
chelator EGTA, IKK and IκBα phosphorylation was markedly
reduced, similar to what we observe upon coculture with Tregs
(Schmidt et al., 2011). Yet calcineurin inhibition might add to NF-
κB suppression, as p65 phosphorylation was shown to be sensitive
to calcineurin inhibitors (Frischbutter et al., 2011).
It remains possible that NF-κB suppression is not only medi-
ated by Ca2+ suppression, but other components of the NF-κB
pathway might be inhibited as well. Our data indicate that PKCθ
activity is unchanged as PKCθ (Thr538) phosphorylation was not
suppressed. Thr538phosphorylation is important forPKCactivity,
interactionwith IKK, andNF-κB activation. This phosphorylation
is generated by the kinase GLK, which is activated downstream of
the TCR (Chuang et al., 2011), and also involves PDK1 activation
downstream of the costimulatory receptor CD28 (Liu et al., 2002;
Lee et al., 2005). However, other phosphorylation sites in PKCθ
have been described. Furthermore, PKCθ might also act upstream
of PLCγ (Manicassamy et al., 2006a) and may also inﬂuence Ca2+
ﬂux though there are controversies in two different studies with
PKCθ deﬁcient mice (Sun et al., 2000; Pfeifhofer et al., 2003; Mani-
cassamy et al., 2006b). It should be subject to further investigations
whether PKCθ recruitment and/or activity or formation of the
CBM complex might be changed in suppressed T cells.
Regarding PKC recruitment, one study demonstrated reduced
recruitment of PKCθ to the immunological synapse in suppressed
murine Tcons (Sumoza-Toledo et al., 2006), yet this was only true
when the Treg and the Tcon were of the same antigen speciﬁcity
and had contact to the same APC. Even when a Treg and a Tcon
with different antigen speciﬁcity had contact to the same APC,
which presented both antigens, no suppression of PKCθ recruit-
ment was observed. However, ﬁndings of Sumoza-Toledo’s group
arenot in accordancewithmanyother studies in that theyobserved
suppression of IL-2 and proliferation only when Treg and Tcon
were of the same antigen speciﬁcity and had contact to the same
APC (Tanchot et al., 2004). We used polyclonal human Tcons
and Tregs in the absence of APCs, which represents a different
setup than the system used by Sumoza-Toledo et al. and ren-
ders it unlikely that suppression of PKCθ recruitment is involved
in our study regarding direct Treg-mediated rapid cytokine sup-
pression. Accordingly, DAG generation, which is crucial for PKCθ
recruitment, was unaffected in suppressed Tcons (Schmidt et al.,
2011).
CONTACT-DEPENDENT CYTOKINE SUPPRESSION IS RETAINED AFTER
REMOVAL OF Tregs
Direct cell contact seemed to be required for suppression of TCR
signaling in Tcons, yet the inhibited state of Tcons was sus-
tained after removal of Tregs from the coculture (Schmidt et al.,
2011). To be suppressed, Tcons must have had cell contact with
pre-activated Tregs for only about 45min. This implies that Tregs,
despite being present in lower numbers than Tcons in vivo, may
have the capacity to suppress several Tcons in a sequential fashion.
Interestingly, we found that suppression of TCR signaling, IL-2
and IFN-γ transcription as well as IFN-γ secretion was retained
upon Treg removal, while suppression of proliferation was not.
Also Sojka et al. (2005) found that murine Tregs can be removed
from the coculture with Tcons and still render Tcons suppressed,
yet in contrast to our results, suppression of proliferation was
observed. However, pre-cocultures were done in the presence of
APCs, so additional effects of Tregs on B7 expression of APCs can-
not be excluded. Our human Tcon:Treg pre-cocultures were done
without APCs for 30–90min. In the study by Sojka et al., 2 h of
coculture was the shortest time period investigated, which already
resulted in approximately 50% suppression while pre-coculture of
≥12 h resulted in 90% suppression of proliferation.
SUPPRESSION OF PROLIFERATION VERSUS CYTOKINE
PRODUCTION – DIFFERENT MECHANISMS?
As suggested by others (Tang and Bluestone, 2008), we propose
that different mechanisms of suppression might be used by Tregs
depending on their activation state, the site of inﬂammation, effec-
tor cell types and point in time of suppression. Furthermore, direct
suppression of T cells or indirect suppression via APC inhibition
both may be relevant in vivo. Along that line, in addition to sup-
pression of T cell priming and proliferation through inhibition
of APCs by Tregs as described by many groups, direct suppres-
sion of CD8+ T cell effector function independently of repressed
proliferation in vivo has been described (Mempel et al., 2006),
underscoring the relevance of direct T cell suppression by Tregs.
Further, it was shown that Treg-mediated suppression of IFN-γ
production by CD4+ T cells can occur without concomitant sup-
pression of proliferation in vivo (Sojka and Fowell, 2011). How-
ever, the importance of direct suppression of TCR signaling and,
consequently, rapid suppression of IL-2 and IFN-γ transcription
in vivo remains elusive to date.
Our data might suggest that at least three different mechanisms
of human Tcon suppression may operate. First, rapid suppres-
sion of Ca2+, NFAT, and NF-κB signaling results in inhibition of
cytokine production,which requires Treg pre-activation, is favored
by cell contact, retained upon Treg removal and seems to be inde-
pendent of CTLA-4, APCs, and IL-2 deprivation (Oberle et al.,
2007; Schmidt et al., 2011). Second, based on our data, we pro-
pose that direct suppression of human Tcon proliferation seems
to require prolonged contact to Tregs and may be independent of
Ca2+ and cytokine suppression. In line with that,mice with CD4+
Tcell-speciﬁc double deﬁciency of STIM1andSTIM2displaymas-
sive T cell proliferation despite undetectable store-operated Ca2+
inﬂux (Oh-Hora et al., 2008). In addition, a marked decrease in
Treg numbers contributes to lymphoproliferation in these mice.
However, alternative modes of Ca2+ entry might compensate for
the absence of STIM, e.g., Cav calcium channels might operate
when their inhibition by STIM1 is lacking (Park et al., 2010; Wang
et al., 2010). It remains to be shown whether, despite suppres-
sion of IL-2 transcription, residual IL-2 might be sufﬁcient to
drive proliferation several days after Treg removal. Depending on
the strength of stimulation, IL-2 amounts and, thus, the effect on
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proliferation may differ. Third, suppression of APCs by Tregs via
CTLA-4 contributes to suppression of Tcon proliferation in the
presence of APCs.
IS CD28 SIGNALING AFFECTED IN Tcons UPON
SUPPRESSION BY Tregs?
Proliferation and activation of T cells does not only require TCR
stimulation but also a second, costimulatory signal (Acuto and
Michel, 2003). CD28, the most prominent costimulatory recep-
tor, is expressed on naïve and activated T cells and is triggered
by its ligands CD80 and CD86, which are expressed on activated
APCs and at low levels on long-term activated T cells. Phospho-
inositide 3-kinase (PI3K), which generates phosphatidylinositol
3,4,5-trisphosphate (PIP3), is one of the key effectors downstream
of CD28 and facilitates activation of PDK1 and one of its tar-
gets, the kinase Akt (protein kinase B, PKB). PTEN is a lipid
phosphatase that negatively regulates the PI3K/Akt pathway by
dephosphorylation of PIP3 into PIP2. TCR-induced activation of
the transcription factors AP-1, NFAT, and in particular NF-κB is
directly inﬂuenced and ampliﬁed by CD28 signaling.
Thus far, the inﬂuence of Tregs on CD28 signaling in Tcons
is unclear, although several hints from the literature support the
hypothesis that Tregs might suppress CD28 signaling in addition
to TCR signaling: strong activation or strong CD28 costimulation
can (partially) overcome suppression of Tcons by Tregs. This was
shown for suppression of IL-2 mRNA and protein as well as for
proliferation of murine T cells (Thornton et al., 2004a; Sojka et al.,
2005), and also for proliferation and IFN-γ secretion of human
Tcons (Baecher-Allan et al., 2002), all performed in the pres-
ence of APCs. We used CD28 costimulation to achieve detectable
phosphorylationof TCR signaling proteins and still observedTreg-
mediated suppression. Yet, we have indications that suppression
of Ca2+ and of proliferation was abrogated upon increasing the
strength of stimulation (unpublished observation).
Reversal of Treg-mediated suppression by CD28 costimulation
might involve activation of PI3K/Akt, since different studies imply
that hyperactivation of the PI3K/Akt pathway renders Tcons resis-
tant to Treg-mediated suppression (Wohlfert andClark, 2007). For
example, T cell-speciﬁc TRAF6 deletion led to hyperactivation
of the PI3K/Akt pathway, resistance to Treg-mediated suppres-
sion and T cell-mediated autoimmune disease (King et al., 2006).
However, PI3K/Akt-induced autoimmune disease might also be
attributed to impaired CD95-mediated T cell apoptosis (Ohashi
and Yeh, 2006). In addition, partial resistance to Treg-mediated
suppression was conferred by expression of constitutively active
Akt in T cells (Pierau et al., 2009) or PI3K/Akt activation by IL-15
(Ben Ahmed et al., 2009). These authors did not ﬁnd involvement
of apoptosis in contrast to Pandiyan et al. (2007) who claim that
Tregs deprive responder Tcons of IL-2 or IL-15 and, thus, reduced
Akt activation and survival of murine Tcons was observed. Sim-
ilarly, a slight downregulation of Akt phosphorylation could be
demonstrated in CD8+ T cells upon coculture with Tregs, while
ZAP-70 was unaffected (Kojima et al., 2005). Furthermore, it was
found that effector T cells from juvenile arthritis patients are resis-
tant to suppression due to Akt hyperactivation (Wehrens et al.,
2011). In addition,Cbl-b knockout T cells are resistant to suppres-
sion (Wohlfert et al., 2004),whichmight involve functions of Cbl-b
in anergy as well as its negative inﬂuence on CD28/PI3K signaling.
AlsoNFAT1/4double knockoutT cells,which are partially resistant
to suppression (Bopp et al., 2005), do not require CD28 costim-
ulation to be activated (Ranger et al., 1998), suggesting PI3K/Akt
hyperactivation in these cells.
Since the PI3K/Akt pathway crosstalks with all main TCR sig-
naling pathways, it might be involved in Treg-mediated rapid
suppression. It remains to be analyzed whether hyperactivation
of the PI3K/Akt pathway also abrogates Treg-mediated suppres-
sion of Ca2+, NF-κB, and NFAT. Further, it remains to be shown
whether Tregs might act via inhibition of PI3K/Akt signaling in
human Tcons. However, it is unclear how this would directly
translate into reduced Ca2+ store depletion without concomitant
reduction of, e.g., PLCγ activity. Analyses of known and unknown
pathways downstream of CD28 in Tcons upon suppression by
Tregs remain subject to further investigation.
CONCLUDING REMARKS
A growing body of evidence indicates that Tregs do not use only
one universal mechanism of suppression, but rather an arsenal
of different ones. So far, it is unclear how a Treg “decides” which
mechanism to apply, and whether it can switch from one to the
other and/or apply several modes of suppression simultaneously.
Mechanisms of suppression as well as target T cell susceptibil-
ity to suppression likely differ depending on tissue site, cell types
involved and activation status of target cell and Treg. Further-
more, different Treg subsets exist and further research should
reveal whether these are specialized on a particular suppressive
mechanism.
In the commonly used in vitro suppression assays, not all
aspects of suppression can be detected with a single readout or
point in time, as suppression of proliferation does not necessarily
reﬂect suppression of effector cytokine production. In addition,
effects of Tregs on APCs have to be addressed if these are included
in the assay. Furthermore, it was shown by several groups that
Tregs have to be TCR-activated in order to be suppressive, which
might be particularly important for assays assessing rapid sup-
pression and, thus, leaving little time for the Tregs to get activated
during stimulation of the coculture. Therefore, it is important to
control for potential effects of the pre-activating reagent itself.
A possible control for effects of the pre-activating reagent is the
use of pre-activated Tcons in comparisonwith pre-activated Tregs,
however, human pre-activated Tcons themselves might upregulate
Foxp3 and/or acquire suppressive function. Another possibility is
the use of pre-activating reagents which can be removed com-
pletely after Treg pre-activation, such as covalently platebound
anti-CD3 antibodies.
The knowledge of molecules and signaling pathways affected
in Tcons upon suppression by Tregs might be crucial for their
therapeutic manipulation in the future. In cancer, suppression of
effector T cells is deleterious and breaking the suppressive state
is highly desirable. In contrast, a suppressed state of autoreac-
tive T cells is warranted during autoimmune disease. Further
research is required to elucidate which mechanisms of Treg-
mediated suppression or of target T cell resistance to suppression
aremost important in aparticular disease,andpossible therapeutic
interventions have to be performed extremely carefully.
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